Abstract
Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1688-1697 |
| Number of pages | 10 |
| Journal | Digestive Diseases and Sciences |
| Volume | 59 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2014 |
Keywords
- Epidermal growth factor
- Hepatocellular carcinoma
- Liver cancer stem cells
- Ras/Raf/MAPK
- Sorafenib
ASJC Scopus subject areas
- Physiology
- Gastroenterology
Fingerprint
Dive into the research topics of 'Molecular therapies in hepatocellular carcinoma: What can we target?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS